PMID- 26850287
OWN - NLM
STAT- MEDLINE
DCOM- 20170626
LR  - 20181202
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 19
IP  - 6
DP  - 2016 Jun
TI  - A global economic model to assess the cost-effectiveness of new treatments for 
      advanced breast cancer in Canada.
PG  - 619-29
LID - 10.3111/13696998.2016.1151431 [doi]
AB  - Objective Considering the increasing number of treatment options for metastatic 
      breast cancer (MBC), it is important to develop high-quality methods to assess 
      the cost-effectiveness of new anti-cancer drugs. This study aims to develop a 
      global economic model that could be used as a benchmark for the economic 
      evaluation of new therapies for MBC. Methods The Global Pharmacoeconomics of 
      Metastatic Breast Cancer (GPMBC) model is a Markov model that was constructed to 
      estimate the incremental cost per quality-adjusted life years (QALY) of new 
      treatments for MBC from a Canadian healthcare system perspective over a lifetime 
      horizon. Specific parameters included in the model are cost of drug treatment, 
      survival outcomes, and incidence of treatment-related adverse events (AEs). 
      Global parameters are patient characteristics, health states utilities, 
      disutilities, and costs associated with treatment-related AEs, as well as costs 
      associated with drug administration, medical follow-up, and end-of-life care. The 
      GPMBC model was tested and validated in a specific context, by assessing the 
      cost-effectiveness of lapatinib plus letrozole compared with other widely used 
      first-line therapies for post-menopausal women with hormone receptor-positive 
      (HR+) and epidermal growth factor receptor 2-positive (HER2+) MBC. Results When 
      tested, the GPMBC model led to incremental cost-utility ratios of CA$131 811 per 
      QALY, CA$56 211 per QALY, and CA$102 477 per QALY for the comparison of lapatinib 
      plus letrozole vs letrozole alone, trastuzumab plus anastrozole, and anastrozole 
      alone, respectively. Results of the model testing were quite similar to those 
      obtained by Delea et al., who also assessed the cost-effectiveness of lapatinib 
      in combination with letrozole in HR+/HER2 + MBC in Canada, thus suggesting that 
      the GPMBC model can replicate results of well-conducted economic evaluations. 
      Conclusions The GPMBC model can be very valuable as it allows a quick and valid 
      assessment of the cost-effectiveness of any new treatments for MBC in a Canadian 
      context.
FAU - Beauchemin, C
AU  - Beauchemin C
AD  - a Faculte de pharmacie , Universite de Montreal , Montreal , Quebec , Canada ;
FAU - Letarte, N
AU  - Letarte N
AD  - a Faculte de pharmacie , Universite de Montreal , Montreal , Quebec , Canada ;
AD  - b Departement de pharmacie , Centre hospitalier de l'Universite de Montreal - 
      Hopital Notre-Dame , Montreal , Quebec , Canada ;
FAU - Mathurin, K
AU  - Mathurin K
AD  - a Faculte de pharmacie , Universite de Montreal , Montreal , Quebec , Canada ;
FAU - Yelle, L
AU  - Yelle L
AD  - c Departement de medecine , Centre hospitalier de l'Universite de Montreal - 
      Hopital Notre-Dame , Montreal , Quebec , Canada.
FAU - Lachaine, J
AU  - Lachaine J
AD  - a Faculte de pharmacie , Universite de Montreal , Montreal , Quebec , Canada ;
LA  - eng
PT  - Journal Article
DEP - 20160302
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Nitriles)
RN  - 0 (Quinazolines)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (Triazoles)
RN  - 0VUA21238F (Lapatinib)
RN  - 2Z07MYW1AZ (Anastrozole)
RN  - 7LKK855W8I (Letrozole)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Anastrozole
MH  - Antineoplastic Agents/administration & dosage/adverse 
      effects/*economics/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Canada
MH  - Cost-Benefit Analysis
MH  - Disease Progression
MH  - Female
MH  - Health Services/*economics/statistics & numerical data
MH  - Humans
MH  - Lapatinib
MH  - Letrozole
MH  - Markov Chains
MH  - Models, Econometric
MH  - Neoplasm Metastasis
MH  - Nitriles/economics/therapeutic use
MH  - *Quality-Adjusted Life Years
MH  - Quinazolines/economics/therapeutic use
MH  - Receptor, ErbB-2/biosynthesis
MH  - Receptors, Estrogen/biosynthesis
MH  - Receptors, Progesterone/biosynthesis
MH  - Terminal Care/economics
MH  - Trastuzumab/economics/therapeutic use
MH  - Triazoles/economics/therapeutic use
OTO - NOTNLM
OT  - Advanced breast cancer
OT  - Cost-effectiveness
OT  - Cost-utility
OT  - Markov model
EDAT- 2016/02/07 06:00
MHDA- 2017/06/27 06:00
CRDT- 2016/02/07 06:00
PHST- 2016/02/07 06:00 [entrez]
PHST- 2016/02/07 06:00 [pubmed]
PHST- 2017/06/27 06:00 [medline]
AID - 10.3111/13696998.2016.1151431 [doi]
PST - ppublish
SO  - J Med Econ. 2016 Jun;19(6):619-29. doi: 10.3111/13696998.2016.1151431. Epub 2016 
      Mar 2.